Angiotensin-receptor blockade, cancer, and concerns
Lancet Oncol
.
2010 Sep;11(9):819; author reply 821-2.
doi: 10.1016/S1470-2045(10)70163-7.
Authors
Peter A Meredith
,
Gordon T McInnes
PMID:
20816377
DOI:
10.1016/S1470-2045(10)70163-7
No abstract available
Publication types
Comment
Letter
MeSH terms
Angiotensin II Type 1 Receptor Blockers / adverse effects*
Clinical Trials as Topic
Humans
Meta-Analysis as Topic
Neoplasms / chemically induced*
Research Design
Substances
Angiotensin II Type 1 Receptor Blockers